SOPHiA GENETICS (NASDAQ:SOPH) Stock Rating Upgraded by Zacks Research

SOPHiA GENETICS (NASDAQ:SOPH) was upgraded by Zacks Research to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other research firms have also recently issued reports on SOPH. HC Wainwright initiated coverage on SOPHiA GENETICS in a report on Monday. They issued a “buy” rating and a $12.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, BTIG Research restated a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $9.00.

SOPHiA GENETICS Stock Down 1.5%

Shares of SOPH opened at $6.40 on Tuesday. The firm has a market capitalization of $536.90 million, a price-to-earnings ratio of -12.31 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The business’s fifty day moving average price is $5.34 and its two-hundred day moving average price is $5.06. SOPHiA GENETICS has a 52 week low of $2.92 and a 52 week high of $6.77.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. On average, analysts predict that SOPHiA GENETICS will post -0.58 earnings per share for the current year.

Insider Activity

In other SOPHiA GENETICS news, CEO Ross Muken sold 9,838 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.22, for a total transaction of $51,354.36. Following the completion of the sale, the chief executive officer owned 670,651 shares in the company, valued at approximately $3,500,798.22. The trade was a 1.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Abhimanyu Verma sold 5,285 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.10, for a total value of $26,953.50. Following the completion of the transaction, the chief technology officer directly owned 192,171 shares in the company, valued at approximately $980,072.10. This trade represents a 2.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 176,711 shares of company stock worth $959,913. Corporate insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the period. Akre Capital Management LLC increased its stake in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Hodges Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the first quarter worth $2,157,000. Royce & Associates LP acquired a new stake in SOPHiA GENETICS in the fourth quarter worth $2,009,000. Finally, Sei Investments Co. acquired a new stake in SOPHiA GENETICS in the first quarter worth $1,772,000. Institutional investors own 31.59% of the company’s stock.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $12 price target, suggesting meaningful upside from current levels and boosting sentiment around SOPHiA GENETICS’s longer-term growth story.
• Positive Sentiment: The same research note laid out an improving earnings path, with SOPHiA GENETICS expected to narrow losses in 2026-2027 and turn profitable by FY2028, while projecting stronger earnings in FY2029 and FY2030.
• Neutral Sentiment: The company announced it will report second-quarter 2026 results on August 4, which typically increases trading interest as investors position ahead of the earnings release. SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
• Neutral Sentiment: A media appearance featuring the CEO discussing how AI could personalize patient therapies reinforces the company’s AI-driven precision medicine narrative, but it is not a direct financial catalyst. SOPHiA GENETICS CEO says AI will personalize patient therapies
• Negative Sentiment: The analyst estimates still point to continued losses in the near term, including FY2026 EPS of ($0.58) and FY2027 EPS of ($0.20), which may temper enthusiasm despite the bullish target price.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.